End-of-day quote
BURSA MALAYSIA
03:30:00 10/05/2024 am IST
|
5-day change
|
1st Jan Change
|
0.45
MYR
|
+9.76%
|
|
+11.11%
|
+1.12%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
24.32
|
41.92
|
105.6
|
144.1
|
99.61
|
61.06
|
Enterprise Value (EV)
1 |
34.53
|
54.86
|
99.5
|
134.4
|
80.72
|
55.67
|
P/E ratio
|
-5.36
x
|
-10.9
x
|
6.18
x
|
-29.1
x
|
13.1
x
|
-3.77
x
|
Yield
|
-
|
-
|
-
|
1.56%
|
-
|
-
|
Capitalization / Revenue
|
0.93
x
|
1.51
x
|
111
x
|
80.8
x
|
3.51
x
|
6.38
x
|
EV / Revenue
|
1.32
x
|
1.98
x
|
105
x
|
75.4
x
|
2.85
x
|
5.81
x
|
EV / EBITDA
|
-11.8
x
|
-30.9
x
|
-16.5
x
|
-33
x
|
11.8
x
|
-3
x
|
EV / FCF
|
-5.87
x
|
-39.3
x
|
-44.8
x
|
-26.9
x
|
-22.5
x
|
-
|
FCF Yield
|
-17%
|
-2.54%
|
-2.23%
|
-3.72%
|
-4.45%
|
-
|
Price to Book
|
1.23
x
|
2.63
x
|
10.3
x
|
7.67
x
|
2.56
x
|
2.73
x
|
Nbr of stocks (in thousands)
|
1,03,510
|
1,03,510
|
1,03,510
|
1,24,210
|
1,30,210
|
1,37,210
|
Reference price
2 |
0.2350
|
0.4050
|
1.020
|
1.160
|
0.7650
|
0.4450
|
Announcement Date
|
19/10/18
|
09/10/19
|
30/10/20
|
29/10/21
|
25/10/22
|
29/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
26.16
|
27.73
|
0.9513
|
1.784
|
28.36
|
9.574
|
EBITDA
1 |
-2.936
|
-1.774
|
-6.022
|
-4.068
|
6.822
|
-18.57
|
EBIT
1 |
-3.907
|
-2.924
|
-6.056
|
-4.335
|
6.024
|
-19.92
|
Operating Margin
|
-14.94%
|
-10.54%
|
-636.61%
|
-243.08%
|
21.24%
|
-208.08%
|
Earnings before Tax (EBT)
1 |
-4.379
|
-3.516
|
-6.442
|
-4.293
|
6.182
|
-20
|
Net income
1 |
-4.535
|
-3.84
|
17.1
|
-4.293
|
7.21
|
-19.05
|
Net margin
|
-17.34%
|
-13.85%
|
1,797.49%
|
-240.7%
|
25.42%
|
-198.96%
|
EPS
2 |
-0.0438
|
-0.0371
|
0.1652
|
-0.0399
|
0.0586
|
-0.1181
|
Free Cash Flow
1 |
-5.881
|
-1.394
|
-2.221
|
-5.001
|
-3.589
|
-
|
FCF margin
|
-22.48%
|
-5.03%
|
-233.41%
|
-280.39%
|
-12.66%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
0.0182
|
-
|
-
|
Announcement Date
|
19/10/18
|
09/10/19
|
30/10/20
|
29/10/21
|
25/10/22
|
29/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
10.2
|
12.9
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
6.08
|
9.66
|
18.9
|
5.39
|
Leverage (Debt/EBITDA)
|
-3.474
x
|
-7.295
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-5.88
|
-1.39
|
-2.22
|
-5
|
-3.59
|
-
|
ROE (net income / shareholders' equity)
|
-20.6%
|
-21.5%
|
-49.1%
|
-30.5%
|
25.3%
|
-
|
ROA (Net income/ Total Assets)
|
-6.21%
|
-4.69%
|
-15.7%
|
-16%
|
11.6%
|
-
|
Assets
1 |
73.01
|
81.79
|
-108.6
|
26.83
|
61.92
|
-
|
Book Value Per Share
2 |
0.1900
|
0.1500
|
0.1000
|
0.1500
|
0.3000
|
0.1600
|
Cash Flow per Share
2 |
0.0700
|
0.0400
|
0.0600
|
0.1000
|
0.1700
|
0.0100
|
Capex
1 |
0.94
|
2.21
|
0.35
|
3.96
|
1.33
|
0.4
|
Capex / Sales
|
3.59%
|
7.99%
|
36.91%
|
222.18%
|
4.69%
|
4.13%
|
Announcement Date
|
19/10/18
|
09/10/19
|
30/10/20
|
29/10/21
|
25/10/22
|
29/03/24
|
|
1st Jan change
|
Capi.
|
---|
| +1.12% | 11.87M | | -16.58% | 8.44B | | +58.90% | 3.96B | | -39.78% | 2.52B | | -10.33% | 2.44B | | -8.91% | 2.22B | | -2.53% | 1.98B | | -19.90% | 1.58B | | -38.30% | 1.3B | | +2.19% | 1.05B |
Medical & Diagnostic Laboratories
|